Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.02 AUD
Change Today -0.001 / -5.56%
Volume 860.0
AGX On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 11:22 PM 04/23/15 All times are local (Market data is delayed by at least 15 minutes).

agenix ltd (AGX) Snapshot

Open
A$0.02
Previous Close
A$0.02
Day High
A$0.02
Day Low
A$0.02
52 Week High
05/19/14 - A$0.02
52 Week Low
10/8/14 - A$0.01
Market Cap
2.3M
Average Volume 10 Days
79.9K
EPS TTM
A$-0.0039
Shares Outstanding
135.8M
EX-Date
11/16/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENIX LTD (AGX)

Related News

No related news articles were found.

agenix ltd (AGX) Related Businessweek News

No Related Businessweek News Found

agenix ltd (AGX) Details

Agenix Limited, a biotechnology company, commercializes next generation drugs and diagnostics in Australia. The company commercializes ThromboView, a patented radio-labeled monoclonal antibody, which completed two FDA Phase II human clinical trials for the detection of blood clots in human body. It also commercializes DiagnostIQ, a rapid point-of-care diagnostic platform for a various human health applications. Agenix Limited is based in Melbourne, Australia.

agenix ltd (AGX) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: A$144.3K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$130.0K
Manager of New Drug Development - Agenix Biop...
Total Annual Compensation: A$43.8K
Compensation as of Fiscal Year 2014.

agenix ltd (AGX) Key Developments

Agenix and OKS Settle Writ

Agenix Ltd. has agreed with OKS AGX Inc. to settle the Supreme Court proceedings commenced by OKS. As announced to the market on December 24, OKS commenced proceedings involving claims arising from a $5 million share subscription agreement entered into between Agenix and OKS in March 2008. It made no claims concerning the conduct of any current Agenix board member or personnel. Following discovery of the existence of the writ, which had been issued, but not served, Agenix determined that it was in the best interests of the company that the litigation be settled. The key components of the settlement transaction are as follows: Agenix to provide and maintain OKS with a 10% shareholding in the total issued capital of Agenix for a period of two years or until a point immediately preceding a merger or acquisition transaction by Agenix, whichever occurs first. OKS to be assigned all rights, title and interest in the Thromboview project.

Agenix Limited Reports Preliminary Earnings Results for the Half Year Ended December 31, 2014

Agenix Limited reported preliminary earnings results for the half year ended December 31, 2014. For the period, the company reported revenue from continuing operations of $2,024, down 89%. Loss from continuing operations after tax attributable to members was $307,608, decreased 21%. Net loss for the period attributable to members was $499,309, decreased 18%.

Agenix Ltd., Annual General Meeting, Nov 12, 2014

Agenix Ltd., Annual General Meeting, Nov 12, 2014., at 11:30 AUS Eastern Standard Time. Location: BDO Melbourne Boardroom. Agenda: To receive the financial report and the reports of the directors and auditors for the year ended 30 June 2014; to consider adoption of remuneration report; to consider issue of securities to Mr. Craig Graeme Chapman in lieu of directors fees; and to deal with any other business which may generally be brought forward in accordance with the company's Constitution and the Corporations Act 2001.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGX:AU A$0.02 AUD -0.001

AGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGX.
View Industry Companies
 

Industry Analysis

AGX

Industry Average

Valuation AGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 204.7x
Price/Book 1.9x
Price/Cash Flow 2.4x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENIX LTD, please visit www.agenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.